Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q8N2W9

UPID:
PIAS4_HUMAN

ALTERNATIVE NAMES:
PIASy; Protein inhibitor of activated STAT protein 4; Protein inhibitor of activated STAT protein gamma

ALTERNATIVE UPACC:
Q8N2W9; O75926; Q96G19; Q9UN16

BACKGROUND:
The protein E3 SUMO-protein ligase PIAS4, with alternative names PIASy and Protein inhibitor of activated STAT protein gamma, is a key player in the sumoylation process. It enhances the sumoylation of key transcription factors and proteins involved in DNA repair, gene silencing, and cellular signaling pathways such as STAT, Wnt, and p53/TP53. Its ability to interact with UBE2I and promote sumoylation of proteins like TCF4 and RNF168 underscores its critical role in cellular regulation and response to DNA damage.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of E3 SUMO-protein ligase PIAS4 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.